Pharmavize sold majority stake to Mentha Capital

MP Corporate Finance acted as the exclusive financial advisor to Pharmavize’s owners, in the sale of a majority stake in Pharmavize NV, a Belgium-based pharmaceutical CDMO, to Mentha Capital, a Dutch financial investor, in order to pursue a Buy-&-Build strategy.

As part of its efforts to further concentrate on its growth as high-quality provider of contract development and manufacturing as well as regulatory services to the pharmaceutical industry, Pharmavize’s shareholders agreed to sell a majority to Dutch private equity firm Mentha Capital.

Pharmavize provides the highest possible standard of CMC development services to a broad customer base from emerging bio-tech to tier-one pharmaceutical companies. Pharmavize is a contractor specialized in the development and manufacturing of early phase clinical studies and is operating a well-respected regulatory & compliance consultancy department. The company is serving a broad customer base from emerging bio-tech to tier-one pharmaceutical companies from all over the world, including Europe, the United States and Japan.

The participation of Mentha Capital adds to Pharmavize a strong and entrepreneurial partner to successfully further develop and internationalize the business and support Pharmavize on its growth path through a structured Buy-&-Build strategy.